NASDAQ: ESPREsperion Therapeutics Inc Stock
$2.36-0.23 (-8.88%)
Updated May 17, 2024
ESPR Price
$2.36
Fair Value Price
N/A
Market Cap
$447.13M
52 Week Low
$0.70
52 Week High
$3.40
P/E
-2.43x
P/B
-1.52x
P/S
1.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$229.74M
Earnings
-$86.51M
Gross Margin
81.9%
Operating Margin
-12.14%
Profit Margin
-37.7%
Debt to Equity
-2.27
Operating Cash Flow
-$27M
Beta
0.96
Next Earnings
May 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ESPR Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ESPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ESPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ESPR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ESPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ESPR due diligence checks available for Premium users.
Be the first to know about important ESPR news, forecast changes, insider trades & much more!
ESPR News
Valuation
ESPR fair value
Fair Value of ESPR stock based on Discounted Cash Flow (DCF)
Price
$2.36
Fair Value
$3.39
Undervalued by
30.33%
ESPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ESPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.43x
Industry
-1.01x
Market
30.97x
ESPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.52x
Industry
2.2x
ESPR's financial health
Profit margin
Revenue
$137.7M
Net Income
$61.0M
Profit Margin
44.3%
ESPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ESPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$373.1M
Liabilities
$667.4M
Debt to equity
-2.27
ESPR's short-term assets ($365.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESPR's long-term liabilities ($502.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ESPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$53.8M
Investing
-$73.0k
Financing
$90.6M
ESPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ESPR vs Pharmaceutical Stocks
Esperion Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.